UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Synta Pharmaceutical (SNTA)

Synta Pharmaceutical (SNTA)
0.34 +0.07 (+25.93%) 07/22/16 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime - - (-) -
Quote Overview for Fri, Jul 22nd, 2016
Day Low
0.27
Day High
0.40
Open 0.28
Previous Close 0.27 0.27
Volume 9,322,899 9,322,899
Avg Vol 1,255,640 1,255,640
Stochastic %K 42.22% 42.22%
Weighted Alpha -60.52 -60.52
5-Day Change +0.07 (+25.93%) +0.07 (+25.93%)
52-Week Range 0.15 - 2.23 0.15 - 2.23
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,330
  • Shares Outstanding, K 137,810
  • Annual Sales, $ 0 K
  • Annual Income, $ -68,670 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.07
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.26
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/04/16
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.25 +36.00%
on 07/20/16
Period Open: 0.31
0.40 -15.00%
on 07/22/16
+0.03 (+9.68%)
since 06/22/16
3-Month
0.25 +36.00%
on 07/20/16
Period Open: 0.37
0.45 -24.44%
on 05/13/16
-0.03 (-8.11%)
since 04/22/16
52-Week
0.15 +126.67%
on 02/08/16
Period Open: 2.14
2.23 -84.75%
on 08/11/15
-1.80 (-84.11%)
since 07/22/15

Most Recent Stories

More News
STRATEGIC MINERALS ANNOUNCES TERMINATION OF BUSINESS COMBINATION AGREEMENT WITH IBERAMERICAN

/CNW/ - Further to the press release dated June 17, 2024, Strategic Minerals Europe Corp. (CBOE: SNTA) (FRA: 26K0) (OTCQB: SNTAF) ("Strategic Minerals" or the...

SNTAF : 0.0001 (-95.24%)
SNTA : 0.34 (+25.93%)
STRATEGIC MINERALS ANNOUNCES CHANGE TO THE BOARD OF DIRECTORS

/CNW/ - Strategic Minerals Europe Corp. (CBOE: SNTA) (OTCQB: SNTAF) (FRA: 26K0) ("Strategic" or the "Company"), a company focused on the production,...

SNTAF : 0.0001 (-95.24%)
SNTA : 0.34 (+25.93%)
STRATEGIC MINERALS REPORTS FOURTH QUARTER AND FULL-YEAR 2023 FINANCIAL RESULTS

/CNW/ - Strategic Minerals Europe Corp. (Cboe: SNTA) (FRA: 26K0) (OTCQB: SNTAF) ("Strategic Minerals" or the "Company"), a company focused on the production,...

SNTAF : 0.0001 (-95.24%)
SNTA : 0.34 (+25.93%)
STRATEGIC MINERALS ISSUES COMMON SHARES IN SATISFACTION OF INTEREST PAYMENT OBLIGATIONS TO CERTAIN CONVERTIBLE DEBENTURE HOLDERS

/CNW/ - Strategic Minerals Europe Corp. (NEO: SNTA) (OTCQB: SNTAF) (FRA: 26K0) ("Strategic Minerals" or "the Company"), a company focused on the production,...

SNTAF : 0.0001 (-95.24%)
SNTA : 0.34 (+25.93%)
Strategic Minerals Provides Update on the Suspension of the Penouta Project Section C Permit

/CNW/ - Strategic Minerals Europe Corp. (NEO: SNTA) (FRA: 26K0) (OTCQB: SNTAF) ("Strategic Minerals" or the "Company"), wishes to provide an update on the...

SNTAF : 0.0001 (-95.24%)
SNTA : 0.34 (+25.93%)
STRATEGIC MINERALS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS

/CNW/ - Strategic Minerals Europe Corp. (NEO: SNTA), (FRA: 26K0), (OTCQB: SNTAF) ("Strategic Minerals" or the "Company"), a company focused on the production,...

SNTAF : 0.0001 (-95.24%)
SNTA : 0.34 (+25.93%)
Strategic Minerals Provides Update on the Suspension of the Penouta Project Section C Permit

/CNW/ - Strategic Minerals Europe Corp. (NEO: SNTA) (FRA: 26K0) (OTCQB: SNTAF) ("Strategic Minerals" or the "Company"), wishes to provide an update on the...

SNTAF : 0.0001 (-95.24%)
SNTA : 0.34 (+25.93%)
Strategic Minerals Europe Receives Spanish Court Decision Regarding the Penouta Project Section C Permit

/CNW/ - Strategic Minerals Europe Corp. (NEO: SNTA) (FRA: 26K0) (OTCQB: SNTAF) ("Strategic Minerals" or the "Company"), today announces that the Superior Court...

SNTAF : 0.0001 (-95.24%)
SNTA : 0.34 (+25.93%)
STRATEGIC MINERALS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS

/CNW/ - Strategic Minerals Europe Corp. (NEO: SNTA) (FRA: 26K0) (OTCQB: SNTAF) ("Strategic Minerals" or the "Company"), a company focused on the production,...

SNTAF : 0.0001 (-95.24%)
SNTA : 0.34 (+25.93%)
Strategic Minerals Announces Increased Gross Revenue Royalty Interest of Electric Royalties on Penouta Mine

/CNW/ - Strategic Minerals Europe Corp. (NEO: SNTA) (FRA: 26K0) (OTCQB: SNTAF) ("Strategic Minerals" or the "Company"), a company focused on the production,...

SNTAF : 0.0001 (-95.24%)
ELEC.VN : 0.140 (+3.70%)
SNTA : 0.34 (+25.93%)
ELECF : 0.1065 (+6.50%)
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That's Heating Up

/PRNewswire/ -- USA News Group - A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this...

ONCY : 0.5680 (-0.80%)
ARAV : 0.0401 (-13.39%)
KTRA : 0.2154 (-6.31%)
ONC.TO : 0.78 (-2.50%)
RHHBY : 38.5800 (+0.21%)
CRBU : 0.7331 (-5.90%)
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –December 1, 2022 – USA News Group  –  A series of new Fast Track designations have been handed out by the United States...

ONCY : 0.5680 (-0.80%)
ARAV : 0.0401 (-13.39%)
KTRA : 0.2154 (-6.31%)
ONC.TO : 0.78 (-2.50%)
RHHBY : 38.5800 (+0.21%)
CRBU : 0.7331 (-5.90%)
Latest Set of FDA Fast Track Designations Causing Optimism in Biotech Sector

USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this week, causing a flurry of activity in the markets for the worthy...

ONCY : 0.5680 (-0.80%)
ARAV : 0.0401 (-13.39%)
KTRA : 0.2154 (-6.31%)
ONC.TO : 0.78 (-2.50%)
RHHBY : 38.5800 (+0.21%)
CRBU : 0.7331 (-5.90%)
Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting

/PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Announces One-for-Fifty Reverse Stock Split

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting

/PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (Kintara or the Company), a biopharmaceutical company focused on the development of new solid tumor...

KTRA : 0.2154 (-6.31%)
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That's Heating Up

/PRNewswire/ -- USA News Group - A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this...

ONCY : 0.5680 (-0.80%)
ARAV : 0.0401 (-13.39%)
KTRA : 0.2154 (-6.31%)
ONC.TO : 0.78 (-2.50%)
RHHBY : 38.5800 (+0.21%)
CRBU : 0.7331 (-5.90%)
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –December 1, 2022 – USA News Group  –  A series of new Fast Track designations have been handed out by the United States...

ONCY : 0.5680 (-0.80%)
ARAV : 0.0401 (-13.39%)
KTRA : 0.2154 (-6.31%)
ONC.TO : 0.78 (-2.50%)
RHHBY : 38.5800 (+0.21%)
CRBU : 0.7331 (-5.90%)
Latest Set of FDA Fast Track Designations Causing Optimism in Biotech Sector

USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this week, causing a flurry of activity in the markets for the worthy...

ONCY : 0.5680 (-0.80%)
ARAV : 0.0401 (-13.39%)
KTRA : 0.2154 (-6.31%)
ONC.TO : 0.78 (-2.50%)
RHHBY : 38.5800 (+0.21%)
CRBU : 0.7331 (-5.90%)
Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting

/PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Announces One-for-Fifty Reverse Stock Split

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting

/PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (Kintara or the Company), a biopharmaceutical company focused on the development of new solid tumor...

KTRA : 0.2154 (-6.31%)

Business Summary

SYNTA PHARMACEUTICALS CORP. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 0.47
1st Resistance Point 0.40
Last Price 0.34
1st Support Level 0.27
2nd Support Level 0.21
3rd Support Level N/A

See More

52-Week High 2.23
Fibonacci 61.8% 1.44
Fibonacci 50% 1.19
Fibonacci 38.2% 0.94
Last Price 0.34
52-Week Low 0.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.